All In Biotech

Drug Trial Radar · NCT05918692

A Phase 1 Study of BMF-500 in Adults With Acute Leukemia

A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study of BMF-500, an Oral Covalent FLT3 Inhibitor, in Adults With Acute Leukemia

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Jul 26, 2023

Primary completion

Jan 1, 2026

Study completion Apr 30, 2026

Sponsor

Lead sponsor
Biomea Fusion Inc.Industry
Sponsor type
Industry
First posted
Jun 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • BMF-500Drug

    Investigational Product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety and tolerability of BMF-500 by incidence of Treatment Emergent Adverse Events (TEAEs).Time frame: At the end of each 28 Day cycle for a maximum of 32 cycles
  2. Evaluate the safety and tolerability of BMF-500 by incidence of Serious Adverse Events (SAEs).Time frame: At the end of each 28 Day cycle for a maximum of 32 cycles
  3. Determine the recommended Phase 2 Dose (RP2D) of BMF-500.Time frame: At the end of 28 day Dose-Limiting Toxicities (DLT) observation Period
  4. Determine the recommended Phase 2 Dose (RP2D) of BMF-500.Time frame: At the end of 28 day Dose-Limiting Toxicities (DLT) observation Period
  5. Determine the recommended Phase 2 Dose (RP2D) of BMF-500.Time frame: At the end of 28 day Dose-Limiting Toxicities (DLT) observation Period
  6. Determine the recommended Phase 2 Dose (RP2D) of BMF-500.Time frame: At the end of 28 day Dose-Limiting Toxicities (DLT) observation Period

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Phoenix, Arizona

  • City of Hope National Medical Center

    Duarte, California

  • University of California, San Francisco

    San Francisco, California

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Mayo Clinic

    Jacksonville, Florida

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • University of Kentucky - Markey Cancer Center

    Lexington, Kentucky

  • Mayo Clinic

    Rochester, Minnesota

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • Texas Oncology-PA USOR

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Virginia Cancer Specialists

    Gainesville, Virginia

  • Fred Hutchinson Cancer Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.